Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05464082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

Study acronym: TOWARDS-II
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 24, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary endpoint reworded 1 of 3 changed
See other at-risk trials from University of Utah

Record History

  1. Primary endpoint(s) modified Secondary endpoints: details revised at 1 of 7 entries · Study description expanded, about 1 wordv10 Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv9
  3. Eligibility criteria expanded, about 43 wordsv8 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: Sep 30, 2025 to Sep 30, 2026 Completion date: Sep 30, 2027 to Sep 30, 2028v7 Show 1 more changeShow less
    • Completion date: Sep 30, 2027 to Sep 30, 2028
  5. Eligibility criteria shortened, about 40 wordsv6 See this version in full on ClinicalTrials.gov ↗
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Suspended to Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  3. Trial status: Not Yet Recruiting to Suspended Sponsor's reason: Accrual suspended pending completion of amendment Start date changed from estimate of Dec 31, 2022 to Jan 6, 2023v3 Show 1 more changeShow less
    • Start date changed from estimate of Dec 31, 2022 to Jan 6, 2023
  4. Start date: Sep 30, 2022 to Dec 31, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Trial Details
NCT Number NCT05464082
Lead Sponsor University of Utah
Collaborators: United States Department of Defense
Conditions Breast Cancer Recurrent
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov